Welcome to our dedicated page for Aptevo Therapeutics SEC filings (Ticker: APVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aptevo Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology company developing immune-oncology candidates based on ADAPTIR and ADAPTIR-FLEX platforms. Its 8-K reports record clinical updates for mipletamig in acute myeloid leukemia, annual financial results, material agreements, executive and board changes, and other public-company events.
The company’s proxy and registration filings disclose shareholder voting matters, proposed charter and administrative amendments, Nasdaq share-issuance approvals, common-stock financing arrangements, and capital-structure information related to its standby equity purchase agreement. These filings also provide formal context for governance, securities issuance mechanics, and the funding disclosures associated with Aptevo’s oncology pipeline.
Aptevo Therapeutics Inc. is asking stockholders to vote at a virtual annual meeting on August 21, 2026 on four key items. Stockholders will elect two directors, Zsolt Harsanyi and Barbara Lopez Kunz, to serve until the 2029 annual meeting, and vote on ratifying Baker Tilly US, LLP as independent auditor for 2026.
Investors will also cast a non-binding advisory "say‑on‑pay" vote on executive compensation for 2025 and consider approving the Fourth Amended and Restated 2018 Stock Incentive Plan, which would add 145,000 shares (market value $633,650 as of July 23, 2026) to the equity pool, on top of 7,360 shares remaining. There were 1,517,945 shares of common stock outstanding as of the July 23, 2026 record date.
The Board reports that 71% of directors are independent and all Audit, Compensation, and Nominating and Corporate Governance committee members are independent. The refreshed stock plan includes features such as no option repricing without stockholder approval, minimum one‑year vesting (with limited exceptions), a $1,000,000 annual cap on non‑employee director compensation, and clawback provisions tied to company policies and applicable law.
Aptevo Therapeutics Inc. reported a new solid tumor strategy built around a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone. Announced on July 27, 2026, this backbone is designed to strengthen its oncology pipeline and expand partnering opportunities.
The backbone is intended to recognize Nectin-4 on tumors and PD-L1 on tumor and immune-suppressive cells, supporting radiopharmaceuticals, T-cell engagers and other immune-modulating therapies that combine tumor targeting, immune activation and payload delivery. Aptevo highlights that this approach leverages its ADAPTIR and ADAPTIR-FLEX platforms, complements its lead AML candidate mipletamig, and aligns with preclinical work on APVO451 and radiopharmaceutical therapeutics.
Aptevo Therapeutics Inc. entered into a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund, under which CARE will reimburse up to $1,499,951 of eligible costs to support IND‑enabling studies for APVO451, Aptevo’s trispecific antibody candidate for solid tumors. The project is expected to run through June 2028, with payments tied to milestones, reporting obligations, and an approved budget, and requires Aptevo to provide at least matching non‑state contributions. Aptevo retains intellectual property generated under the project, subject to commercialization and public‑benefit commitments, and highlighted in a press release that the award is non‑dilutive and strategically supports advancement of its nectin‑4‑targeted trispecific immunotherapy platform.
Niowave, Inc. reported beneficial ownership of 151,723 shares of Aptevo Therapeutics Inc. common stock, representing 12.18% of the class based on 1,246,105 shares outstanding as of May 13, 2026. The filing is a Schedule 13G signed June 22, 2026, and states the position was not acquired to change or influence control.
NIOWAVE, INC., a ten percent owner of Aptevo Therapeutics Inc., filed an initial ownership report on Form 3. The filing shows direct ownership of 98,522 shares of Common Stock. It also lists a warrant to buy 53,201 shares of Common Stock at an exercise price of $8.00 per share, expiring on May 25, 2031.
Aptevo Therapeutics Inc. executive Mary Jo Janatpour, SVP and Chief Scientific Officer, filed an initial Form 3 reporting her beneficial ownership of the company’s Common Stock. The filing shows she held 0 shares of Common Stock directly following the reporting date.
Aptevo Therapeutics entered a 50/50 strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programs combining Aptevo’s multispecific antibody platforms with Niowave’s radioisotopes, including Actinium-225. The partners will start with a proof-of-concept study using assets such as APVO455 and a Nectin-4–targeting approach.
To align interests, Niowave purchased 98,522 Aptevo common shares and warrants to buy 53,201 additional shares in a private placement for about $500,000 at a combined price of $5.075 per share. The warrants are exercisable at $8.00 per share until May 25, 2031, subject to a beneficial ownership cap of 4.99% or, at Niowave’s election, up to 9.99%. Niowave may also buy up to 97,373 more shares over time, capped so its stake does not exceed 19.99% of Aptevo’s common stock.
Aptevo Therapeutics reported another quarterly loss and raised doubt about its ability to continue as a going concern. For the three months ended March 31, 2026, the company recorded a net loss of $6.7 million, driven by research and development expenses of $3.9 million and general and administrative costs of $2.9 million.
Cash and cash equivalents fell to $14.5 million from $21.6 million at year-end, with $8.0 million used in operating activities in the quarter. Management states that recurring losses, negative operating cash flow, and limited cash resources create substantial doubt about Aptevo’s ability to continue as a going concern over the next year, and the company expects to rely on equity facilities and other financings to fund its oncology pipeline.
Aptevo Therapeutics reported a first-quarter 2026 business update centered on its lead AML drug candidate mipletamig, executive changes, and added financing capacity. In the RAINIER Phase 1b/2 trial in frontline acute myeloid leukemia with venetoclax plus azacitidine, 31 evaluable patients showed an 87% clinical benefit rate, with 81% achieving complete remission or complete remission with incomplete hematologic recovery and 65% achieving complete remission. No cytokine release syndrome has been observed in frontline patients, and 52% of remission patients reached measurable residual disease-negative status. The company completed a planned leadership transition, appointing Jeff Lamothe as CEO and Marvin White as Executive Chair. Aptevo ended March 31, 2026 with $14.5 million in cash and cash equivalents and has a new $60 million Standby Equity Purchase Agreement to support upcoming clinical and strategic milestones.